The collaboration will provide AI-enhanced pathology analysis across four Houston Research Institute medical centers in Texas.
HistoIndex announced a partnership with Houston Research Institute to expand access to advanced diagnostic testing services for patients with metabolic dysfunction-associated steatohepatitis (MASH).
The Singapore-based company specializes in AI-driven digital pathology solutions for chronic liver disease. Houston Research Institute is a research institute focused on clinical trials in hepatology and gastroenterology, with particular emphasis on metabolic liver disease.
Under the partnership, all four Houston Research Institute medical centers—Houston Research Institute Pasadena, Houston Research Institute Sugar Land, Houston Research Institute, and Houston Research Institute Medical Center—will have access to HistoIndex’s integrated diagnostic offering. The service combines expert histopathological evaluation by experienced pathologists with advanced AI-based biopsy analysis.
The collaboration includes HistoIndex’s proprietary AI-based diagnostic test, FibroSIGHT Plus, which delivers quantitative assessment of liver fibrosis in MASH liver biopsies. This complements standard-of-care histological evaluation for steatosis, lobular inflammation, ballooning, and fibrosis.
“Partnering with Houston Research Institute represents a significant step forward in our mission to bring quantitative, AI-enabled pathology into MASH clinical care,” says Dr Yukti Choudhury, chief development officer at HistoIndex, in a release. “We provide a unique AI-enhanced diagnostic service package to our clients, and by centralizing both traditional and AI-enhanced workflows, we are able to streamline turnaround times, maintain rigorous quality standards across every specimen.”
Expanding Diagnostic Capabilities
The partnership aims to enhance diagnostic capabilities across Houston Research Institute’s centers by integrating traditional pathology methods with AI-based analysis tools.
“This partnership with HistoIndex expands our ability to offer advanced, high-quality diagnostic services to patients with MASH,” says Mazen Noureddin, MD, director at Houston Research Institute and co-chairman of the Board Summit and Pinnacle Clinical Research, in a release. “Integrating expert histopathology with quantitative AI-based fibrosis analysis strengthens our diagnostic capabilities and supports more informed clinical decision-making across our liver centers.”
MASH is a progressive form of metabolic dysfunction-associated steatotic liver disease characterized by steatosis, ballooning degeneration, and inflammation. The condition can lead to fibrosis, cirrhosis, liver failure, and increased risk of liver cancer. Pathologist assessment of liver biopsy remains the gold standard for diagnosing and assessing MASH severity.
Founded in 2010, HistoIndex develops stain-free, automated imaging solutions for visualizing and quantifying fibrosis in biological tissues. The company combines biophotonic technology with AI-based analysis to provide tools for assessing fibrosis changes and drug efficacy in clinical research and pharmaceutical development.
ID 81373155 © Ben Schonewille | Dreamstime.com
